Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human CDC7 Protein, N-His

Catalog #:   YHA09001 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: O00311
Protein length: Met1-Thr232
Overview

Catalog No.

YHA09001

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Met1-Thr232

Predicted molecular weight

28.79 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

O00311

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

HsCdc7, CDC7L1, Cell division cycle 7-related protein kinase, CDC7-related kinase, huCdc7, CDC7

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human CDC7 protein
References

Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration., PMID:40340943

Immunohistochemistry and machine learning study of DNA replication-associated proteins in uterine epithelial tumors and precursor lesions., PMID:40220589

Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients., PMID:40186268

Pan-cancer analysis of CDC7 in human tumors: Integrative multi-omics insights and discovery of novel marine-based inhibitors through machine learning and computational approaches., PMID:40120182

Recent advances in CDC7 kinase inhibitors: Novel strategies for the treatment of cancers and neurodegenerative diseases., PMID:40090297

Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer., PMID:40034665

Experimental, Theoretical, and In Silico Studies of Potential CDC7 Kinase Inhibitors., PMID:39829445

Clinical significance and pro-oncogenic function of DBF4 in clear cell renal cell carcinoma., PMID:39815239

Proteome-wide forced interactions reveal a functional map of cell-cycle phospho-regulation in S. cerevisiae., PMID:39618027

The Genomic Landscape of Wilson Disease in a Pan India Disease Cohort and Population-Scale Data., PMID:39535360

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer., PMID:39412086

Assembly, Activation, and Helicase Actions of MCM2-7: Transition from Inactive MCM2-7 Double Hexamers to Active Replication Forks., PMID:39194567

CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation., PMID:39054323

DBF4, not DRF1, is the crucial regulator of CDC7 kinase at replication forks., PMID:38865090

RAD18 O-GlcNAcylation promotes translesion DNA synthesis and homologous recombination repair., PMID:38719812

CK1δ/ε kinases regulate TDP-43 phosphorylation and are therapeutic targets for ALS-related TDP-43 hyperphosphorylation., PMID:38677657

CDC7 inhibition drives an inflammatory response and a p53-dependent senescent-like state in breast epithelial cells., PMID:38555567

Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer., PMID:38520730

Potts Hamiltonian Models and Molecular Dynamics Free Energy Simulations for Predicting the Impact of Mutations on Protein Kinase Stability., PMID:38350894

The ORFIUS complex regulates ORC2 localization at replication origins., PMID:38288445

Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy., PMID:38278156

Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase., PMID:38205514

Evaluation of cell proliferation marker CDC-7 in salivary adenoid cystic carcinoma., PMID:38183819

Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer., PMID:37992591

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade., PMID:37980406

Protein kinase Cdc7 supports viral replication by phosphorylating Avibirnavirus VP3 protein., PMID:37902398

Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7., PMID:37866880

Persistent Acetylation of Histone H3 Lysine 56 Compromises the Activity of DNA Replication Origins., PMID:37811746

CDC7 kinase inhibitors: a survey of recent patent literature (2017-2022)., PMID:37735909

Cdc7 kinase is required for postnatal brain development., PMID:37584256

Rif1 restrains the rate of replication origin firing in Xenopus laevis., PMID:37516798

DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy., PMID:37497004

Multiple suppressing small interfering RNA for cancer treatment-Application to triple-negative breast cancer., PMID:37478121

Azaindole derivatives as potential kinase inhibitors and their SARs elucidation., PMID:37423125

PTBP1 enforces ATR-CHK1 signaling determining the potency of CDC7 inhibitors., PMID:37378325

ATR kinase supports normal proliferation in the early S phase by preventing replication resource exhaustion., PMID:37336885

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study., PMID:36970056

Homozygous DBF4 mutation as a cause of severe congenital neutropenia., PMID:36841265

Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening., PMID:36725843

Claspin is Required for Growth Recovery from Serum Starvation through Regulating the PI3K-PDK1-mTOR Pathway in Mammalian Cells., PMID:36720467

Analysis of the expression and prognostic significance of DDK complex in Hepatocarcinoma., PMID:36609254

CDC7 Expression in Selected Odontogenic Tumors., PMID:36483932

Degree of stemness predicts micro-environmental response and clinical outcomes of diffuse large B-cell lymphoma and identifies a potential targeted therapy., PMID:36426371

WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe., PMID:36338546

Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis., PMID:35926565

The interaction between the Dbf4 ortholog Chiffon and Gcn5 is conserved in Dipteran insect species., PMID:35789507

A function for ataxia telangiectasia and Rad3-related (ATR) kinase in cytokinetic abscission., PMID:35754741

Alcohol consumption, blood DNA methylation and breast cancer: a Mendelian randomisation study., PMID:35708873

CDC7 as a novel biomarker and druggable target in cancer., PMID:35657477

The structural basis of Cdc7-Dbf4 kinase dependent targeting and phosphorylation of the MCM2-7 double hexamer., PMID:35614055

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human CDC7 Protein, N-His [YHA09001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only